“Targanta enlisted the expertise of Maxiom Group due to its extensive Oracle experience and reputation for delivering high quality services for life science companies,” said George Eldridge, Senior Vice President, Finance and Administration and Chief Financial Officer of Targanta Therapeutics. “The rapid deployment of the systems was a remarkable accomplishment and a testament to the teamwork by Targanta, Maxiom Group, and Oracle. As we move toward filing a new drug application with the United States Food and Drug Administration for our first product candidate, the Oracle E-Business Suite should provide us a solid foundation on which to build our commercial platform most efficiently. We are very pleased with our choice of Maxiom Group to help us reach our goals as we continue to grow as an organization.”
The Oracle E-Business Suite implementation, which included general ledger, accounts payable, iProcurement, iExpense and accounts receivable applications, is intended to allow Targanta to centralize its financial management processes, which had previously been divided between offices in the United States and Canada.
“Life science companies such as Targanta typically face the need to standardize and integrate a range of operational functions, including financial processes and reporting,” said Oracle Group Vice President, Healthcare and Life Sciences, Neil de Crescenzo. “By leveraging the functionality of the Oracle E-Business Suite and industry expertise of partners like Maxiom Group, companies are better equipped to quickly and cost-effectively make more informed decisions, improve compliance and increase operational efficiencies.”
“At this important time in Targanta’s evolution, it was clear the company was ready to move to the next level and deploy the Oracle E-Business Suite,” said Kelly Schmitz, Vice President of Enterprise Applications at Maxiom Group. “We believe this was a smart strategy for the company, as this solution should enable Targanta to achieve its growth objectives in an efficient and systematic manner. We are very proud that Targanta placed its confidence in us as they continue to progress in an increasingly complex and competitive business environment.”
Maxiom Group is a Certified Partner in the Oracle PartnerNetwork.
ABOUT TARGANTA THERAPEUTICS CORPORATION Targanta Therapeutics Corporation is a privately held biopharmaceutical company focused on developing and commercializing novel antibacterial agents to treat serious infections (either treated or acquired) in the hospital or other institutional settings. Its pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic for which Targanta intends to submit an NDA for U.S. regulatory approval in early 2008, and a number of antibacterial agents in pre-clinical development. The company has operations in Cambridge, MA, Indianapolis, IN, Montreal, Québec, and Toronto, Ontario, Canada. For further information about Targanta, visit the company website, www.targanta.com.
ABOUT THE ORACLE PARTNERNETWORK Oracle PartnerNetwork is a global business network of more than 19,500 companies who deliver innovative software solutions based on Oracle software. Through access to Oracle’s premier products, education, technical services, marketing and sales support, the Oracle PartnerNetwork program provides partners with the resources they need to be successful in today’s global economy. Oracle partners are able to offer their customers leading-edge solutions backed by Oracle’s position as the world's largest enterprise software company. Partners who are able to demonstrate superior product knowledge, technical expertise and a commitment to doing business with Oracle qualify for the Oracle Certified Partner levels. http://oraclepartnernetwork.oracle.com
ABOUT MAXIOM GROUP Maxiom Group is a leading strategic business and IT consulting firm exclusively serving the life sciences industry. We help transform emerging, established and mature biotechnology, pharmaceutical and medical device companies at each stage of their life cycle by solving mission critical business issues. From drug discovery and development, to clinical trials, to commercial launch and sustained market leadership, Maxiom Group clients rely on our unique focus, insight and approach. For more information please visit www.maxiomgroup.com.
